Dr. Athiya Agarwal has submitted a prior intimation to stock exchanges for the proposed acquisition of shares in Dr. Agarwal's Health Care Limited under SEBI's Substantial Acquisition of Shares and Takeovers (SAST) Regulations. The filing, dated February 24, 2026, outlines the acquisition of 21,15,180 shares representing 0.67% of the company's share capital.

Transaction Details

The proposed share transfer is structured as an inter-se transfer between promoter group members who are immediate relatives. The transaction involves no monetary consideration as the shares will be transferred by way of gift.

Regulatory Framework and Exemptions

The acquisition falls under the exemption provided in Regulation 10(1)(a)(i) of SEBI SAST Regulations, 2011, which covers inter-se transfers of shares amongst immediate relatives. This exemption eliminates the requirement for making an open offer to public shareholders. The transaction is characterized as a private family arrangement aimed at streamlining the family's assets and businesses.

Shareholding Pattern Changes

The inter-se transfer will result in changes to individual shareholdings within the promoter group while maintaining the overall promoter group shareholding percentage.

Compliance and Declarations

Dr. Athiya Agarwal, as the acquirer, has provided necessary declarations confirming compliance with applicable disclosure requirements under Chapter V of the Takeover Regulations. The filing includes confirmation that all conditions specified under Regulation 10(1)(a) regarding exemptions have been duly met. Both the transferor and transferee have committed to comply with ongoing disclosure requirements as mandated by SEBI regulations.

The transaction represents a straightforward reorganization of shareholding within the promoter group of Dr. Agarwal's Health Care Limited, with no impact on the company's overall promoter group shareholding or operational structure.

Dr. Agarwal's Health Care Limited has announced that ICRA Limited has reaffirmed and assigned credit ratings for the company's debt facilities totaling ₹200 crores. The rating action was communicated through a letter dated February 23, 2026, and disclosed to stock exchanges in compliance with Regulation 30 of SEBI listing regulations.

Credit Rating Details

ICRA Limited has taken comprehensive rating actions across the company's debt portfolio, covering both existing facilities and enhanced limits.

Rating Significance

The ICRA AA- (Stable) rating indicates high credit quality with very low credit risk, while the ICRA A1+ rating for short-term facilities represents the highest safety regarding timely payment of financial obligations. The stable outlook suggests that the rating is unlikely to change in the near term.

Enhanced Credit Facilities

A significant development in this rating action is the enhancement of unallocated limits to ₹126.20 crores, for which ICRA has both reaffirmed existing ratings and assigned new ratings. These unallocated limits provide the company with flexibility to utilize funds across long-term and short-term requirements as per business needs.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication was signed by Thanikainathan Arumugam, Company Secretary and Compliance Officer, ensuring proper corporate governance protocols.